🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#ASCO2023 Interesting work by Brendan Guercio, Chung-Han Lee 李宗翰, MD/PhD, and colleagues from Memorial Sloan Kettering Cancer Center showing an association between high fiber intake and prolonged PFS in urothelial and renal cell carcinoma. Validation is warranted. Abstract 4598.

@kidneycancer brings together the #kidneycancer community for research & practice updates twice yearly #IKCS symposia. I have had the privilege to help plan over the years w/ Eric A. Singer, MD, MA, MS, FACS, FASCO Chung-Han Lee 李宗翰, MD/PhD Bradley McGregor Stephanie Berg et al. Save the date for Nov 10-11, 2023 in Nashville!

Special thanks to our superstar #IKCSNA23 planning committee! Phillip Pierorazio Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) Stephanie Berg #MariaCarlo #DanGeynisman Chung-Han Lee 李宗翰, MD/PhD #JodieMaranchie Sarah P. Psutka MD MS #KiranVirdee Yousef Zakharia kidneycancer.org/ikcs/2023-ikcs…

Pembrolizumab plus lenvatinib yielded anti-tumor activity and a manageable safety profile as a first-line treatment option for patients with advanced non–clear cell renal cell carcinoma regardless of histology. #kicsm #ASCO23 | ASCO Chung-Han Lee 李宗翰, MD/PhD ow.ly/8yIL50OPUH4

Pleased to share The Lancet Oncology LENVA-PEMBRO across RCC variant histologies: papillary RCC, unclRCC and chromophobe RCC … interim ESMO - Eur. Oncology #ESMO22 and final Chung-Han Lee 李宗翰, MD/PhD ASCO #ASCO23 full text: authors.elsevier.com/a/1hP1c5EIIgLp… Thanks to all who change rareRCC pts Tx!

Lenvatinib/Pembrolizumab Benefit Is Upheld in Advanced RCC, Including ICI-Pretreated and Naïve Subgroups Chung-Han Lee 李宗翰, MD/PhD Memorial Sloan Kettering Cancer Center KidneyCAN #KCRS23 #kcsm ow.ly/Vup250Pc5I3

The association between FGFR3 alterations and response to platinum-based chemotherapy in locally advanced and metastatic #UrothelialCarcinoma. Gopa Iyer Memorial Sloan Kettering Cancer Center joins Sam S. Chang MD, MBA Vanderbilt Urology in this discussion on UroToday > bit.ly/41G3smP European Urology

“The responses remained durable in a subset of patients who were previously treated but ICI naïve, but also in patients who received ICIs as prior systemic therapy,” said Chung-Han Lee, MD, PhD. #kicsm | KidneyCAN Chung-Han Lee 李宗翰, MD/PhD ow.ly/C1Zv50PfBsg

Lenvatinib and pembrolizumab continued to show clinical activity in patients with metastatic RCC, including in subsets of patients who had received or were naïve to checkpoint inhibitors. Chung-Han Lee 李宗翰, MD/PhD Memorial Sloan Kettering Cancer Center Kidney Cancer #KCRS23 #kcsm ow.ly/VAZR50PfvWF

Longer follow-up data from the Study 111/KN146 showed that lenvatinib and pembrolizumab produced durable responses lasting at least 18 months in many patients with metastatic RCC. Chung-Han Lee 李宗翰, MD/PhD Memorial Sloan Kettering Cancer Center Kidney Cancer #KCRS23 #kcsm ow.ly/f5Tp50PfvZ6

#KEYNOTEB61 study reveals promising results of lenvatinib + pembrolizumab combo in non-clear cell #RCC. Chung-Han Lee 李宗翰, MD/PhD Memorial Sloan Kettering Cancer Center joins Pedro C Barata, MD MSc FACP Case Comp Cancer Ctr to discuss his significant contributions to #KidneyCancer research. #WatchNow > bit.ly/3Q6JH5f

Thanks SWOG Cancer Research Network for highlighting #PAPMET2 as the trial of the week. Prior IO trials suggest it is time for a randomized trial. Many have contributed to our understanding of this disease--lets keep moving forward! Laurence Albiges Chung-Han Lee 李宗翰, MD/PhD Sumanta K. Pal, MD, FASCO swog.org/clinical-trial…

Thank u Dr K., MD, MS, FASCO 🌎🇺🇸🇪🇺🇺🇦🌏! So appreciative of Bladder Cancer Advocacy Network, who supported work with Gopa Iyer Chung-Han Lee 李宗翰, MD/PhD showing association of diet with immunotherapy benefit in bladder cancer. Excited to now explore impact of diet on irAEs in SWOG Cancer Research Network iCHECKIT bit.ly/3rSPNvT

🎥Chung-Han Lee 李宗翰, MD/PhD of Memorial Sloan Kettering Cancer Center discusses combining lenvatinib and pembrolizumab as a first-line treatment for non-clear cell RCC, aiming to provide a new treatment option for this subgroup: ➡️ow.ly/Izvu50Pv0UX⬅️ #ASCO23 #KCSM #UroOnc #UroSoMe #ImmunoOnc

A life/career update, delayed by a transcontinental move: last month I graduated Memorial Sloan Kettering Cancer Center fellowship, and this week I joined the GU Med Onc faculty group at UCSF Helen Diller Family Comprehensive Cancer Ctr! Owe so much to my mentors Chung-Han Lee 李宗翰, MD/PhD Robert Motzer MD and many others, and so excited for what’s to come.

So lucky to have had the chance to work with Kelly Fitzgerald. UCSF is so lucky to have you. We are all expecting great things from you.

Ending my last clinic Memorial Sloan Kettering Cancer Center with dinner with Gopa Iyer and Ritesh Kotecha. So grateful to work 12 years with the best mentor I have ever had, Robert Motzer MD. So proud of Kelly Fitzgerald who is starting UC San Francisco . Excited to start a new chapter of my career on 8/14.

Great to see everyone at ESMO. Kidney Cancer keep up the good work. Our patients need you.

Very excited to share with you incredibly promising data for #zanzalintinib (#XL092) in patients with #kidneycancer. A million thanks to @kidneycancer for allowing us to present this data in a highlighted oral session at #IKCSNA23! See my slides/thoughts here: (1/9)

Rarely do I see such flawed analysis in an abstract that it makes me read the full article. irAEs Can Predict PFS and OS In Patients w/ Metastatic Renal Cell Carcinoma Treated w/ Immune Checkpoint Inhibitors - PubMed (nih.gov)